# A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

> **NCT05001373** · PHASE1 · UNKNOWN · sponsor: **International AIDS Vaccine Initiative** · enrollment: 56 (estimated)

## Conditions studied

- Hiv

## Interventions

- **BIOLOGICAL:** Core-g28v2 60mer mRNA Vaccine
- **BIOLOGICAL:** eOD-GT8 60mer mRNA Vaccine

## Key facts

- **NCT ID:** NCT05001373
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-12
- **Primary completion:** 2023-06-20
- **Final completion:** 2024-07-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001373, "A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05001373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*